HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [unchecked revision] | [unchecked revision] |
No edit summary |
No edit summary |
||
| Line 101: | Line 101: | ||
|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| | |Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes||Disease|| || || || || ||FQR|| | ||
| || | | || | ||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Acute promyelocytic leukaemia with PML::RARA fusion | |||
|Disease | |||
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D. | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion | |||
|Disease | |||
|Christine Bryke, MD<br>Beth Israel Deaconess Medical Center, Boston, MA | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with CBFB::MYH11 fusion | |||
|Disease | |||
|Christine Bryke, MD <br> Beth Israel Deaconess Medical Center, Boston, MA | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with DEK::NUP214 fusion | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with RBM15::MRTFA fusion | |||
|Disease | |||
|Jennelle C. Hodge, PhD, FACMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with BCR::ABL1 fusion | |||
|Disease | |||
|Kay Weng Choy MBBS, Monash Medical Centre | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with KMT2A rearrangement | |||
|Disease | |||
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D. | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with MECOM rearrangement | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with NUP98 rearrangement | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with NPM1 mutation | |||
|Disease | |||
|Xinjie Xu, PhD, FACMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with CEBPA mutation | |||
|Disease | |||
|Paul Defazio, MSc, Monash Health | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia, myelodysplasia-related | |||
|Disease | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with other defined genetic alterations | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with minimal differentiation | |||
|Disease | |||
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia without maturation | |||
|Disease | |||
|Jennelle C. Hodge, PhD, FACMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myeloid leukaemia with maturation | |||
|Disease | |||
|Jennelle C. Hodge, PhD, FACMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute basophilic leukaemia | |||
|Disease | |||
|Ashwini Yenamandra PhD FACMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute myelomonocytic leukaemia | |||
|Disease | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute monocytic leukaemia | |||
|Disease | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute erythroid leukaemia | |||
|Disease | |||
|Ashwini Yenamandra PhD FACMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute megakaryoblastic leukaemia | |||
|Disease | |||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University, Portland, OR | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Myeloid sarcoma | |||
|Disease | |||
|Yalda Naeini, MD, School of Medicine at University of California Los Angeles Fabiola Quintero-Rivera, MD, FACMG, School of Medicine at University of California Irvine | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Myeloid neoplasm post cytotoxic therapy | |||
|Disease | |||
|Shawn A. Silver, DO, Shashi Shetty, Ph.D. | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Myeloid neoplasms associated with germline predisposition | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Myeloid proliferations associated with Down syndrome | |||
|Disease | |||
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion | |||
|Disease | |||
|Tracy Tucker, PhD, FCCMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Mixed-phenotype acute leukaemia with KMT2A rearrangement | |||
|Disease | |||
|Tracy Tucker, PhD, FCCMG | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute leukaemia of ambiguous lineage with other defined genetic alterations | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Mixed-phenotype acute leukaemia, B/myeloid | |||
|Disease | |||
|Priyatharsini Nirmalanantham, MD and Shashi Shetty, PhD | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Mixed-phenotype acute leukaemia, T/myeloid | |||
|Disease | |||
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Mixed-phenotype acute leukaemia, rare types | |||
|Disease | |||
|Elicia Goodale, MD, Medical University of South Carolina Daynna Wolff, PhD, Medical University of South Carolina | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute leukaemia of ambiguous lineage, NOS | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Acute undifferentiated leukaemia | |||
|Disease | |||
|Amelia Nakanishi, MD and Shashi Shetty, PhD | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm | |||
|Disease | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
|Blastic plasmacytoid dendritic cell neoplasm | |||
|Disease | |||
|Hao Liu, MD and Daynna J. Wolff, PhD | |||
| | |||
| | |||
| | |||
| | |||
|JH_MS | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | | | ||
| Line 279: | Line 819: | ||
| | | | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| Line 366: | Line 906: | ||
| | | | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| Line 402: | Line 942: | ||
| | | | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||
| | | || || || || || || || || | ||
| || | | || | ||
|- | |- | ||